Evidence for a potent antiinflammatory effect of rosiglitazone

Priya Mohanty, Ahmad Aljada, Husam Ghanim, Deborah Hofmeyer, Devjit Tripathy, Tufail Syed, Waddah Al-Haddad, Sandeep Dhindsa, Paresh Dandona

Research output: Contribution to journalArticle

331 Scopus citations

Abstract

We have recently demonstrated a potent antiinflammatory effect of troglitazone, an agonist of peroxisome proliferates activated receptor γ (PPARγ) and a partial agonist of PPARα in both the nondiabetic obese and diabetic obese subjects. We have now investigated the antiinflammatory actions of rosiglitazone, a selective PPARγ agonist. Eleven nondiabetic obese subjects and 11 obese diabetic subjects were each given 4 mg of rosiglitazone daily for a period of 6 wk. Fasting blood samples were obtained at 0, 1, 2, 4, 6, and 12 wk (6 wk after the cessation of rosiglitazone). Eight obese subjects and five obese diabetic subjects were also included in the study as control groups. Fasting blood samples were obtained from the control groups at 0, 1, 2, 4, and 6 wk only. Nuclear factor κB (NFκB)-binding activity in mononuclear cells, plasma monocyte chemoattractant protein-1 (MCP-1), TNF-α, soluble intercellular adhesion molecule-1, C-reactive protein (CRP), and serum amyloid A (SAA) were measured. Blood glucose concentration changed significantly at 8 wk only in the obese diabetic subjects after rosiglitazone treatment for 6 wk, whereas insulin concentration decreased significantly at 6 wk in both groups. NFκB-binding activity in mononuclear cell nuclear extract fell in both obese and obese diabetic subjects (P < 0.02). Rosiglitazone treatment resulted in a reduction in plasma MCP-1 and CRP in both groups (P < 0.05). Plasma TNF-α and SAA concentrations were inhibited significantly in the obese group (P < 0.05) but not in the obese diabetic subjects. NFκB-binding activity and plasma MCP-1, CRP, SAA, and TNF-α did not change in the obese and obese diabetic control groups. We conclude that rosiglitazone, a selective PPARγ agonist, exerts an antiinflammatory effect at the cellular and molecular level, and in plasma. These observations may have implications for atherogenesis in the long term in subjects treated with rosiglitazone and possibly other thiazolidinediones.

Original languageEnglish (US)
Pages (from-to)2728-2835
Number of pages108
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number6
DOIs
StatePublished - Jun 1 2004

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Evidence for a potent antiinflammatory effect of rosiglitazone'. Together they form a unique fingerprint.

  • Cite this

    Mohanty, P., Aljada, A., Ghanim, H., Hofmeyer, D., Tripathy, D., Syed, T., Al-Haddad, W., Dhindsa, S., & Dandona, P. (2004). Evidence for a potent antiinflammatory effect of rosiglitazone. Journal of Clinical Endocrinology and Metabolism, 89(6), 2728-2835. https://doi.org/10.1210/jc.2003-032103